SynthesisCJEM2026
Major adverse cardiac events in patients with indeterminate high-sensitivity troponin testing and chest pain: a systematic review.
Synthesis in CJEM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesContemporary high-sensitivity cardiac troponin (hs-cTn) assays can detect very low levels of myocardial injury, leading many emergency department (ED) chest pain patients to exceed the 99th-percentile upper reference limit, despite low risk for myocardial infarction. This systematic review aimed to synthesize evidence quantifying the risk of MACE among ED patients with a single troponin concentration measurement above the 99th percentile reference limit but below diagnostic cutoffs for myocardial infarction.
methodsElectronic searches of MEDLINE, Cochrane Reviews, CINAHL and EMBASE (2002-2025) were conducted. Studies were included if outcomes for patients with indeterminate single hs-Tn measurements were reported or extractable. Patients with ECG findings suggestive of ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) were excluded. Two reviewers independently screened abstracts and extracted data. MACE was defined as acute myocardial infarction (MI), stroke, and cardiovascular mortality 30 days after index ED visit.
resultsThe search strategy yielded 709 potentially relevant citations. Eight studies were included: one randomized controlled trial, three prospective cohort, and four retrospective cohort studies. The incidence of MACE ranged from 0.3 to 14.8%. 46,066 of 129,060 eligible patients (40%) had a second test after an indeterminate result. Risk of bias was high for most observational studies, primarily due to information and incorporation bias, and randomized controlled trials had some concern for bias in the selection of the reported results, randomization process, and intended intervention.
conclusionsIt remains unknown whether patients with an indeterminate hs-Tn result and no serial testing are at increased risk for MACE. More than half of such patients did not receive serial testing. The study demonstrates inconsistent approaches for managing indeterminate troponin results, underscoring the need for physicians to interpret indeterminate values cautiously and consider clinical assessment in low-risk chest pain patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.